表紙
市場調查報告書
商品編碼
1020703

生物晶片的全球市場:現狀分析與未來預測 (2021年∼2027年)

Biochip Market: Current Analysis and Forecast (2021-2027)

出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 293 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球生物晶片的市場規模,2020年達到了112億4745萬美元,預計從2021年到2027年以12.13%的年複合成長率成長。市場主要促進因素,是在慢性疾病增加和醫療基礎設施的整備,在基因組學、蛋白質體學、藥物研發等廣泛領域的普及滲透等。各類型中DNA晶片佔整體38.83%,以及實驗室晶片在預測期間內預計以12.98%的年複合成長率成長。在各地區中,北美各國為最大市場,預計亞太地區也產生迅速的市場成長。

本報告提供全球生物晶片的市場相關分析,市場概要和背景情況、相關法規,市場基本結構和最新形勢,主要的促進、阻礙因素,整體市場規模趨勢預測,各類型、各技術、各用途、各終端用戶、各地區的詳細趨勢,市場競爭狀態,主要企業簡介等調查。

目錄

第1章 分析概要

第2章 分析方法與前提條件

第3章 市場概況

第4章 摘要整理

第5章 新型冠狀病毒感染疾病 (COVID-19) 與生物晶片

第6章 全球生物晶片市場收益趨勢 (2019年∼2027年)

第7章 各種類的市場分析

  • DNA晶片
  • 實驗室晶片
  • 蛋白質晶片
  • 其他

第8章 各技術的市場分析

  • 微陣列
  • 微流體

第9章 各用途的市場分析

  • 藥物研發、開發
  • 疾病診斷
  • 基因學
  • 蛋白質體學
  • 其他

第10章 各終端用戶的市場分析

  • 醫院、診斷中心
  • 教育、研究機關
  • 生物科技、製藥
  • 其他

第11章 各地區的市場分析

  • 北美的生物晶片市場
    • 美國
    • 加拿大
    • 其他的北美各國
  • 歐洲的生物晶片市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲各國
  • 亞太地區的生物晶片市場
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他的亞太地區各國
  • 其他的國家 (RoW)的生物晶片市場

第12章 全球生物晶片市場市場動態

  • 市場促進因素
  • 市場課題
  • 影響分析

第13章 全球生物晶片的市場機會

第14章 全球生物晶片市場趨勢與考察

第15章 法規、法律規範

第16章 需求與供給側面分析

  • 需求面分析
  • 供給側面分析
    • 主要的產品銷售的動向
    • 主要企業聯盟的動向
    • 主要企業擴張、投資、出售的動向
    • 主要的企業合併、收購 (M&A)的動向

第17章 價值鏈分析

第18章 競爭模式

  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 產業的競爭
    • 替代品的可得性
    • 新加入業者的威脅

第19章 企業概要

  • Abbott Laboratories Inc.
  • Agilent Technologies, Inc.
  • PerkinElmer Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories Inc
  • GE Healthcare Inc.
  • Fluidigm Corporation
  • Illumina, Inc.
  • F. Hoffmann-La Roche AG
  • BioMerieux SA

第20章 免責聲明

目錄
Product Code: UMHE21327

A biochip is a little miniaturized device that can perform multiple biochemical reactions at the same time in molecular laboratories. It can quickly screen a variety of biological analytes for varied of applications, including disease diagnosis and the detection of biological substances that are toxic to a system. It is designed based on microarray and microfluidic technologies, among which digital microfluid biochip is highly efficient, and has gained significant popularity in the biochemical field

The adoption of biochips is increasing in various applications in genomics, proteomics, and drug discovery. The advancement of targeted and personalized medicines for the treatment of cancer is influencing the market growth. Other factors such as the rising number of biochips applications, technological advancement in biochips, and rise in healthcare spending facilities are leveling up the biochips market demand. For instance, between 2010 and 2019, health spending in the OECD averaged around 8.7% of GDP every year. In the same time span, however, healthcare spending in the United States increased from 16.3 percent to 17.0 percent of GDP. Moreover, rising funds by government and private organizations in the emerging nations are expected to provide better opportunities for the market

However, The factors such as higher cost biochips and lack of knowledge about biochips are hampering the market growth. Moreover, a lack of awareness among the people about biochips technologies is primarily restricting biochips market growth.

Based on type, the market is fragmented into DNA chips, lab-on-a-chip, proteins chips, and others. The DNA chips segment grabbed the major market share and contributed around 38.83% In 2020. Moreover, the market would reach to USD 9779.80 Mn by 2027 growing with a CAGR of 12.05% during 2021-2017 owing to the owing to high adoption of DNA chip products. However, lab-on-a-chip segment is anticipated to grow at a significant CAGR of 12.98% during the forecast period

Based on the technology, the market is fragmented into microarray and microfluids. The microarray segment of Global Biochips dominated the market with around 61.16% market share. The segment generated the revenue of USD 6,878.61 Mn in 2020 and is expected to grow at a CAGR of 11.73% during the forthcoming years owing to its application in forensics and drug discovery

Based on the application, the market is fragmented into drug discovery & development, disease diagnostics, genomics, proteomics, and others. The drug discovery & development segment of Global Biochips dominated the market with around 33.52% market share. The segment generated the revenue of USD 3,760.35 Mn in 2020 and is expected to grow at a CAGR of 11.91% during the forthcoming years. The demand of drug discovery and development is increasing owing to the to the increased research and development and the involvement of biotech companies

Based on the end-user, the market is fragmented in hospitals & diagnostics centers, academics & research institutes, biotechnology & pharmaceuticals, and others. The hospitals & diagnostics centers segment grabbed the major market share and dominated the market. The segment generated the revenue of worth USD 4,580.11 Mn in 2020 and is expected to reach to USD 10,121.72 Mn by 2027. However, the academics & research institutes segment is expected to witness an exhibit growth during the forecast period

For a better understanding of the market adoption of the Biochip market, the market is analyzed based on its worldwide penetration in the countries such as North America (United States, Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for Biochip and generated revenue of USD 3,826.38 Mn in 2020 owing to the advanced technology for diagnosis and treatment of chronic disorders, availability of private and government funding, etc. However, the Asia-Pacific region would grow at the highest rate during the forecast period

Some of the major players operating in the market Abbott Laboratories Inc., Agilent Technologies, Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories Inc, GE Healthcare Inc., Fluidigm Corporation, Illumina, Inc., F. Hoffmann-La Roche AG, and BioMerieux SA. Several M&A's along with partnerships have been undertaken by these players to develop In-Cabin Sensing Systems

Global Biochip Market was valued at USD 11,247.45 million in 2020 and is projected to expand significantly with a CAGR of 12.13% from 2021-2027F. The Global Biochip Market is expected to witness a boost on account of increasing prevalence of chronic diseases and improvement in the healthcare infrastructure

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Objective of the Study
  • 1.3. Limitation
  • 1.4. Stake Holders
  • 1.5. Currency Used in Report
  • 1.6. Scope of the Global Biochip Market Study

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Methodology for the Global Biochip Market
    • 2.1.1. Main Objective of the Global Biochip Market

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 BIOCHIP AMID COVID-19

6 GLOBAL BIOCHIP MARKET REVENUE, 2019-2027F

7 MARKET INSIGHTS BY TYPE

  • 7.1. DNA Chips
  • 7.2. Lab-On-a-Chip
  • 7.3. Proteins Chips
  • 7.4. Others

8 MARKET INSIGHTS BY TECHNOLOGY

  • 8.1. Microarrays
  • 8.2. Microfluidics

9 MARKET INSIGHTS BY APPLICATION

  • 9.1. Drug Discovery & Development
  • 9.2. Disease Diagnostics
  • 9.3. Genomics
  • 9.4. Proteomics
  • 9.5. Others

10 MARKET INSIGHTS BY END-USER

  • 10.1. Hospitals & Diagnostics Centers
  • 10.2. Academics & Research institutes
  • 10.3. Biotechnology & Pharmaceuticals
  • 10.4. Others

11 MARKET INSIGHTS BY REGION

  • 11.1. NORTH AMERICA BIOCHIP MARKET
    • 11.1.1. United States
    • 11.1.2. Canada
    • 11.1.3. Rest of North America
  • 11.2. EUROPE BIOCHIP MARKET
    • 11.2.1. United Kingdom
    • 11.2.2. Germany
    • 11.2.3. France
    • 11.2.4. Italy
    • 11.2.5. Spain
    • 11.2.6. Rest of Europe
  • 11.3. ASIA PACIFIC BIOCHIP MARKET
    • 11.3.1. China
    • 11.3.2. Japan
    • 11.3.3. India
    • 11.3.4. South Korea
    • 11.3.5. Australia
    • 11.3.6. Rest of Asia Pacific
  • 11.4. REST OF WORLD BIOCHIP MARKET

12 GLOBAL BIOCHIP MARKET DYNAMICS

  • 12.1. Market Drivers
  • 12.2. Market Challenges
  • 12.3. Impact Analysis

13 GLOBAL BIOCHIP MARKET OPPORTUNITIES

14 GLOBAL BIOCHIP MARKET TRENDS & INSIGHTS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

  • 16.1. Demand Side Analysis
  • 16.2. Supply Side Analysis
    • 16.2.1. Top Product Launches
    • 16.2.2. Top Business Partnerships
    • 16.2.3. Top Business Expansions, Investments and Divestitures
    • 16.2.4. Top Merger and Acquisitions

17 VALUE CHAIN ANALYSIS

18 COMPETITIVE SCENARIO

  • 18.1. Porter's Five Forces Analysis
    • 18.1.1. Bargaining power of Supplier
    • 18.1.2. Bargaining power of Buyer
    • 18.1.3. Industry Rivalry
    • 18.1.4. Availability of Substitute
    • 18.1.5. Threat of new Entrants

19 COMPANY PROFILED

  • 19.1. Abbott Laboratories Inc.
  • 19.2. Agilent Technologies, Inc.
  • 19.3. PerkinElmer Inc.
  • 19.4. Thermo Fisher Scientific, Inc.
  • 19.5. Bio-Rad Laboratories Inc
  • 19.6. GE Healthcare Inc.
  • 19.7. Fluidigm Corporation
  • 19.8. Illumina, Inc.
  • 19.9. F. Hoffmann-La Roche AG
  • 19.10. BioMerieux SA

20 DISCLAIMER